Monoclonal antibodies are the basis of modern, targeted therapies. The production of long-lasting antibody-producing hybridoma cells, followed by antibody manufacturing and purification, requires coordinated process steps.

These antibody-producing cells are often generated using the hybridoma technique, in which B cells are fused with myeloma cells. The resulting hybridoma cells combine the antibody-producing capability of B cells with the longevity and robustness of myeloma cells.

PAN-Biotech offers high-quality standard products and customized sterile formulations for efficient and reliable antibody production.